Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Disorder Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KCNK9/TASK3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCNK9/TASK3 Extracellular Loop / Cap Domain Recombinant Protein High purity (>95%), Endotoxin <1 EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View KCNK9 Products |
| Gene Delivery | KCNK9/TASK3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Cell-based assays are the only way to preserve conformation. |
View KCNK9 Products |
| Benchmark Ab | Anti-KCNK9/TASK3 Recombinant Antibody (Sequence of Y4) Recombinant positive control for validation assays. |
View KCNK9 Products |
| Validator | KCNK9/TASK3 siRNA Set For knockdown verification and target specificity validation. |
View KCNK9 Products |
| Related Target A | KCNK3 (TASK1) Highly homologous subfamily partner. Critical for counter-screening to ensure selectivity. |
View KCNK3 Products |
| Related Target B | KCNK5 (TASK2) Related two-pore domain potassium channel used to construct selectivity profiling panels. |
View KCNK5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent antibody screening | Lentivirus Premade Particles for stable cell line generation, preserving native 4-TM topology. |
| Subfamily counter-screening (TASK1/TASK3) | Highly purified KCNK3 and KCNK5 recombinant proteins strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Y4 sequence-derived biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live KCNK9/TASK3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KCNK9/TASK3 therapeutics is intensifying, with major players shifting focus from traditional small-molecule channel blockers to targeted monoclonal antibodies and selective inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting high-selectivity modulators that spare homologous channels like KCNK3 (TASK1) to minimize cardiotoxicity and neurological side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Academic/Biotech Consortia | Breast Cancer, Colorectal Cancer | Native conformation presentation (Need Lentivirus for stable cell line development) |
| Small Molecule Inhibitor | Pharmaceutical Developers | Birk-Barel Syndrome, Sleep Apnea | Selectivity profiling (Need KCNK3/TASK1 and KCNK5/TASK2 counter-screening panels) |
| RNA Therapeutics | Preclinical Startups | Oncological Overexpression | Knockdown validation (Need sequence-verified siRNA set) |